Short answer
Gilead Sciences (GILD) filed its Q3 2025 10-Q quarterly report on Nov 7, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $7.8B (up 3.0% year over year) with net income of $3.1B.
Q3 2025 key financials · XBRL
- Revenue
- $7.8B
- +3.0% YoY · +9.7% QoQ
- Net income
- $3.1B
- +143.6% YoY · +55.7% QoQ
- Operating margin
- 42.8%
- EPS (diluted)
- $2.43
- +140.6% YoY · +54.8% QoQ
Source: XBRL data from the Gilead Sciences (GILD) Q3 2025 10-Q on SEC EDGAR. USD.
Gilead Sciences Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability or margin figures disclosed for the quarter
- No segment or product line performance data mentioned
- No details on cash position, operating cash flow, or capital deployment changes
- No updated guidance or management commentary on near-term outlook or headwinds
Risk Factors
- New regulatory risk: FDA boxed warning (Jan 2024) on CAR T-cell therapies for secondary T-cell malignancies; impacts Yescarta, Tecartus acceptance
- Updated pricing risk: Inflation Reduction Act effects uncertain; increased Medicare Part D discounts (10%-20%) and rebate obligations starting 2023-2025
- Compliance risk: 340B contract pharmacy integrity initiative faces ongoing legal challenges from HHS and states; compliance and litigation remain uncertain
- Operational risk: Supply chain/logistics risks in cell therapy; disruptions at apheresis centers or manufacturing delays could constrain commercialization
- Financial risk: Dependence on 3 U.S. wholesalers (~90% sales) creates revenue volatility due to inventory and purchasing pattern fluctuations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Gilead Sciences quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.